Home - Medical Device Network
How can medical device companies improve the sustainability of clinical products?
Zimmer Biomet agrees to acquire Paragon 28 for $1.2bn
Jan 29, 2025 · Zimmer Biomet has signed a definitive agreement to acquire Paragon 28 for an enterprise value of approximately $1.2bn, which will significantly bolster the former’s foot and …
Company A-Z - Medical Device Network
ARBOR Technology. Rugged MCAs, Medical Tablet PCs, and Embedded Boards and Systems for Medical Terminals
FDA approves BioIntelliSense’s BioButton wearable
Oct 3, 2024 · BioIntelliSense founder and CEO Dr James Mault said: “We are advancing a new standard of care by automating the capture of thousands of multiparameter measurements …
Medline Industries targets $5bn IPO in 2025 - medicaldevice …
Nov 22, 2024 · Medline Industries, a medical supplies provider, is reportedly preparing for an initial public offering (IPO) in the US that could exceed $5bn, as reported by Reuters.. The …
The impact of US tariffs on medtech investments
On 2 April 2025, President Trump introduced “reciprocal tariffs” on multiple countries, setting a baseline tariff of at least 10%. However, several nations faced much steeper rates, including …
Transforming paediatric scoliosis care with digital health innovations
Apr 3, 2025 · Transforming paediatric scoliosis care with digital health innovations. The incorporation of 3D topography scans and AI into the Momentum Spine platform represents a …
The future of the medical devices: Trends for 2025 and beyond
Dec 18, 2024 · The future of the medical devices: Trends for 2025 and beyond. Advancements in artificial intelligence, precision medicine, and digital health pave the way for innovation that …
Medtronic's lead gains FDA approval for use in right ventricle
Apr 28, 2025 · The lead is designed to connect to an implantable defibrillator and claims to be the smallest in the world. Credit: Medtronic plc/PRNewswire. The US Food and Drug …
FDA grants breakthrough status to Roche's VENTANA TROP2
Apr 29, 2025 · It is specifically indicated for patients with advanced or metastatic non-squamous NSCLC without actionable genomic alterations. The device comprises the TROP2 algorithm, …